致敬夢(mèng)想 | 2026藥明康德全球論壇圖文速遞 | Bilingual

世紀(jì)之交的2000年，人類(lèi)首次觸及生命藍(lán)圖的輪廓。那一刻，一個(gè)關(guān)于醫(yī)學(xué)的夢(mèng)想被點(diǎn)亮——更深入地理解疾病，更理性地設(shè)計(jì)藥物，讓改變命運(yùn)的治療，走向更多生命。也正是在這一年，藥明康德誕生。與全球創(chuàng)新者同行，將夢(mèng)想化為篤定的初心。

25年，夢(mèng)想沒(méi)有停留在想象中。它走進(jìn)實(shí)驗(yàn)室，融入臨床中，在一次次協(xié)作與托付里，緩慢生長(zhǎng)，不斷延展。

站在2026年的起點(diǎn)，第14屆藥明康德全球論壇在舊金山如期舉行。來(lái)自世界各地的追夢(mèng)人再度相聚，以“B.O.L.D.”為名，回望走過(guò)的25年，也眺望仍在前方的夢(mèng)想。向那些始終相信科學(xué)、堅(jiān)持創(chuàng)新、并以行動(dòng)推動(dòng)醫(yī)學(xué)向前的人——致敬。

歡迎

在歡迎致辭中，論壇主席、藥明康德副總裁蔡輝博士邀請(qǐng)大家一起回望過(guò)去25年的來(lái)路。她說(shuō)，每年1月的相聚，從來(lái)不只是一次會(huì)議，更像是一種約定：提醒我們生物醫(yī)藥產(chǎn)業(yè)之所以能夠不斷向前，是因?yàn)檫x擇彼此信任、并肩同行。

圍繞論壇長(zhǎng)期堅(jiān)持的主題“B.O.L.D.”，蔡輝博士進(jìn)一步分享了她的理解：BOLD，不只是打破邊界、探索未知，更是在紛繁復(fù)雜的世界中保持清醒、穩(wěn)穩(wěn)走好每一步，并始終把患者放在心中最重要的位置。這是一條堅(jiān)實(shí)而篤定的路，也是一段由無(wú)數(shù)雙手共同托舉、攜手走向未來(lái)的同行之旅。

時(shí)代創(chuàng)新脈動(dòng)

站在本世紀(jì)下一個(gè)25年的起點(diǎn)，我們不禁思考，這一路走來(lái)，產(chǎn)業(yè)取得了哪些令人矚目的突破，又有哪些瓶頸仍待解決？在開(kāi)場(chǎng)討論中，多位行業(yè)領(lǐng)袖從創(chuàng)新突破轉(zhuǎn)化、臨床開(kāi)發(fā)、監(jiān)管與投資等多個(gè)維度切入，回顧過(guò)去，審視當(dāng)下，共同探討未來(lái)的發(fā)展方向。

拜耳執(zhí)行副總裁、制藥業(yè)務(wù)BD&L負(fù)責(zé)人兼Leaps負(fù)責(zé)人Juergen Eckhardt博士回顧了過(guò)去25年間新治療模式的涌現(xiàn)。他表示：“那是一個(gè)令人震撼的時(shí)期。在新治療模式的開(kāi)發(fā)，尤其是在將其真正帶給患者方面，可能都是前所未有的。這些進(jìn)展切實(shí)改變了許多患者的治療范式。”

在肯定顯著進(jìn)步的同時(shí)，嘉賓們也對(duì)行業(yè)仍面臨的深層挑戰(zhàn)保持清醒認(rèn)識(shí)。塔夫茨藥物開(kāi)發(fā)研究中心教授兼高級(jí)研究員Kenneth Kaitin博士指出：“藥物研發(fā)的基本流程在過(guò)去60多年里幾乎沒(méi)有發(fā)生變化，這也由此帶來(lái)了一系列新的挑戰(zhàn)。”

在諸多挑戰(zhàn)之中，如何提升臨床試驗(yàn)效率成為多位嘉賓共同關(guān)注的焦點(diǎn)。MD安德森癌癥中心高級(jí)副總裁兼首席科學(xué)官Giulio Draetta博士指出，與“患者不愿參與復(fù)雜臨床試驗(yàn)”的傳統(tǒng)認(rèn)知不同，現(xiàn)實(shí)中患者往往展現(xiàn)出極大的慷慨與意愿，希望為早期研究提供支持。他認(rèn)為，如果能夠更好地銜接標(biāo)準(zhǔn)治療與臨床試驗(yàn)，在真實(shí)醫(yī)療場(chǎng)景中實(shí)現(xiàn)更高質(zhì)量的執(zhí)行，臨床試驗(yàn)的參與度有望顯著提升。

從罕見(jiàn)病的視角出發(fā)，Parabilis Medicines董事長(zhǎng)、總裁兼首席執(zhí)行官M(fèi)athai Mammen博士補(bǔ)充道，企業(yè)需要更加系統(tǒng)地利用常規(guī)篩查數(shù)據(jù)，主動(dòng)識(shí)別真正患病的潛在受試者。這一做法不僅有助于改善罕見(jiàn)病患者的診斷路徑，也將為相關(guān)領(lǐng)域的臨床試驗(yàn)推進(jìn)帶來(lái)實(shí)質(zhì)性助力。

在提升臨床效率的技術(shù)路徑中，人工智能（AI）被視為重要工具之一。Averin Capital聯(lián)合創(chuàng)始人兼管理合伙人David Berry博士分享了AI在臨床研究中的潛在應(yīng)用前景。他指出，借助AI進(jìn)行臨床研究模擬，已發(fā)展到FDA允許開(kāi)展“無(wú)需直接接觸患者”的研究探索。盡管用AI模擬取代傳統(tǒng)臨床試驗(yàn)在過(guò)去被普遍視為不可能，但這一邊界正在被不斷推動(dòng)。

圍繞“挑戰(zhàn)不可能”這一話(huà)題，本場(chǎng)討論主持人、RA Ventures風(fēng)險(xiǎn)合伙人Laura Shawver博士引用了一句她尤為認(rèn)同的話(huà)：“困難的事情可以立刻去做，不可能的事情只是需要更長(zhǎng)一點(diǎn)時(shí)間。”她表示，隨著時(shí)間推移和能力積累，許多當(dāng)下看似無(wú)法實(shí)現(xiàn)的目標(biāo)，終將被逐一攻克。

創(chuàng)新快車(chē)道

在將科學(xué)真正轉(zhuǎn)化為創(chuàng)新療法、造福病患的進(jìn)程中，哪些候選藥物值得更進(jìn)一步？我們又該如何做出抉擇，讓創(chuàng)新滿(mǎn)足最迫切的醫(yī)療需求？在論壇的第二場(chǎng)專(zhuān)題討論中，多家新銳公司的領(lǐng)軍人物分享了加速新藥研發(fā)的實(shí)踐與策略，以及如何挑戰(zhàn)傳統(tǒng)研發(fā)路徑，探索能夠提升研發(fā)成功率的新技術(shù)、新模式與新理念。

討論伊始，專(zhuān)題討論主持人、Forbion合伙人Jon Edwards博士拋出了一個(gè)基礎(chǔ)卻關(guān)鍵的問(wèn)題：“我們所說(shuō)的‘速度’究竟意味著什么？是充足的資金儲(chǔ)備，還是經(jīng)驗(yàn)豐富、少走彎路的團(tuán)隊(duì)？抑或是被寄予厚望、能夠解決一切問(wèn)題的AI？”

談及AI在加速藥物發(fā)現(xiàn)中的角色，Xaira Therapeutics首席醫(yī)學(xué)官Paulo Fontoura博士表達(dá)了審慎而樂(lè)觀的態(tài)度。他認(rèn)為，AI的價(jià)值不僅在于提升速度，更在于幫助研發(fā)更快接近“真相”。“AI既能加深我們對(duì)生物學(xué)機(jī)制的理解，也能幫助我們將這些機(jī)制精準(zhǔn)匹配到合適的患者身上，從而真正改善治療結(jié)果。”

與此同時(shí)，多位嘉賓也提醒，在追求速度的過(guò)程中，科學(xué)判斷與試驗(yàn)設(shè)計(jì)同樣至關(guān)重要。Tenvie Therapeutics首席執(zhí)行官兼總裁Tony Estrada博士指出，在中樞神經(jīng)系統(tǒng)疾病領(lǐng)域，過(guò)快推進(jìn)有時(shí)反而可能對(duì)靶點(diǎn)理解和生物學(xué)假設(shè)造成干擾，進(jìn)而得出錯(cuò)誤結(jié)論，延緩整個(gè)領(lǐng)域的發(fā)展。

在討論如何“更快做出更好的藥”時(shí)，Dispatch Bio首席執(zhí)行官Sabah ?ney博士將焦點(diǎn)重新拉回患者本身。他強(qiáng)調(diào)，在實(shí)體瘤等疾病領(lǐng)域，患者所承受的時(shí)間壓力極為真實(shí)。“如果我們哪怕晚了兩年，意味著成千上萬(wàn)原本可能受益的患者，最終錯(cuò)失了機(jī)會(huì)。”

Candid Therapeutics董事長(zhǎng)、總裁兼首席執(zhí)行官Ken Song博士則從研發(fā)決策的角度提出了一種更具挑戰(zhàn)性的思維方式——通過(guò)設(shè)計(jì)“正確的實(shí)驗(yàn)”，盡早驗(yàn)證假設(shè)、快速作出取舍。他認(rèn)為，能夠盡早終止不可行項(xiàng)目，本身也是一種效率和責(zé)任的體現(xiàn)。

細(xì)胞和基因療法的時(shí)代承諾

作為近年來(lái)迅速崛起的創(chuàng)新治療模式之一，細(xì)胞和基因療法已為治療多種癌癥和遺傳病帶來(lái)新的希望。2025年，F(xiàn)red Ramsdell博士因在調(diào)節(jié)性T細(xì)胞領(lǐng)域的奠基性工作，榮獲諾貝爾生理學(xué)或醫(yī)學(xué)獎(jiǎng)。與Sonoma Biotherapeutics創(chuàng)始人兼顧問(wèn)Jeffrey Bluestone博士一道，他們回顧了細(xì)胞和基因療法這一領(lǐng)域的發(fā)展歷程與當(dāng)前格局，并對(duì)未來(lái)的重點(diǎn)拓展方向做了展望。

兩位嘉賓重點(diǎn)探討了調(diào)節(jié)性T細(xì)胞相關(guān)的基礎(chǔ)研究如何為細(xì)胞療法治療自身免疫疾病奠定科學(xué)基礎(chǔ)。Jeffrey Bluestone博士指出，諾獎(jiǎng)研究揭示了免疫耐受并非免疫缺失，而是一個(gè)高度主動(dòng)、由進(jìn)化塑造的過(guò)程。調(diào)節(jié)性T細(xì)胞并非生物學(xué)的偶然產(chǎn)物，而是專(zhuān)門(mén)為維持自身組織穩(wěn)態(tài)而進(jìn)化出的關(guān)鍵細(xì)胞譜系。幾乎所有自身免疫疾病以及移植排斥反應(yīng)，都與這些細(xì)胞功能失調(diào)密切相關(guān)，這也為新一代治療策略提供了清晰方向。

Fred Ramsdell博士則進(jìn)一步闡述了調(diào)節(jié)性T細(xì)胞療法相較于傳統(tǒng)藥物模式的獨(dú)特優(yōu)勢(shì)。他表示，這一療法的魅力在于充分利用了進(jìn)化本身的智慧——這些細(xì)胞“知道該去哪里、該做什么”，能夠主動(dòng)維持組織健康。“讓為保護(hù)組織而進(jìn)化出的細(xì)胞，繼續(xù)去完成它們本該承擔(dān)的任務(wù)，本身就是一種極具潛力的治療思路。”

以患者為先：我們肩負(fù)的方向

無(wú)論科學(xué)怎么突破，技術(shù)怎么創(chuàng)新，目標(biāo)最終都應(yīng)回歸到改善患者的生活。圍繞中樞神經(jīng)系統(tǒng)疾病、癌癥、以及心血管疾病這三大“殺手”，三位長(zhǎng)期奮戰(zhàn)在臨床與科研一線(xiàn)的科學(xué)家就各自擅長(zhǎng)的領(lǐng)域展開(kāi)深入交流，探討哪些治療與預(yù)防手段能夠真正改變患者的生活，又有哪些更加患者導(dǎo)向的研發(fā)策略能真正推動(dòng)創(chuàng)新惠及病患。

專(zhuān)題討論主持、Arena BioWorks董事長(zhǎng)兼首席執(zhí)行官Harvey Berger博士在開(kāi)場(chǎng)時(shí)直言，在他看來(lái)，藥物研發(fā)領(lǐng)域面臨的根本問(wèn)題仍是失敗率過(guò)高。“如果失敗率能夠顯著降低，速度本身就不會(huì)成為核心矛盾，患者所獲得的改變將是深刻而持久的。

對(duì)此，斯坦福心血管研究所主任、Greenstone Biosciences聯(lián)合創(chuàng)始人Joseph Wu博士表達(dá)了審慎的樂(lè)觀。他指出，隨著技術(shù)手段的飛速發(fā)展，研究者如今能夠在單細(xì)胞層面解析組織、基因與蛋白變化，并將這些發(fā)現(xiàn)迅速反饋至藥物設(shè)計(jì)與功能驗(yàn)證之中。借助類(lèi)器官等新模型，研發(fā)過(guò)程正逐步形成更高效的閉環(huán)。

在腫瘤領(lǐng)域，帕克癌癥免疫治療研究所首席執(zhí)行官Karen Knudsen博士強(qiáng)調(diào)，創(chuàng)新療法已經(jīng)開(kāi)始在真實(shí)世界中產(chǎn)生深遠(yuǎn)影響。她指出，美國(guó)目前已首次在所有癌癥總體層面實(shí)現(xiàn)五年生存率達(dá)到70%，這一歷史性進(jìn)展，正源于在多種難治性癌癥中的持續(xù)治療創(chuàng)新。

談及神經(jīng)退行性疾病的未來(lái)，2025年科學(xué)突破獎(jiǎng)（Breakthrough Prize）得主，加州大學(xué)舊金山分校Weill神經(jīng)科學(xué)研究所主任Stephen Hauser博士同樣持積極態(tài)度。他認(rèn)為，隨著生物標(biāo)志物和通路研究的成熟，阿爾茨海默病、帕金森病、ALS等疾病的生物學(xué)復(fù)雜性正逐步被拆解。針對(duì)合理靶點(diǎn)、設(shè)計(jì)嚴(yán)謹(jǐn)?shù)捻?xiàng)目，有望在未來(lái)顯著改善全球患者的生活質(zhì)量。

共創(chuàng)未來(lái)

藥明康德聯(lián)席首席執(zhí)行官陳民章博士首先向所有到場(chǎng)的演講嘉賓、合作伙伴以及一路同行的朋友致以由衷的感謝。回望來(lái)路，他將時(shí)間拉回到2000年。那時(shí)的藥明康德，只有四名員工、一間實(shí)驗(yàn)室，卻已懷抱著一個(gè)樸素而堅(jiān)定的信念：科學(xué)，能夠改變生命。25年來(lái)，這份信念從未孤獨(dú)前行。正是在全球創(chuàng)新生態(tài)圈的推動(dòng)下，在一次次突破邊界、一次次勇于承擔(dān)風(fēng)險(xiǎn)的選擇中，在順境與逆境交織的旅程里，大家彼此扶持、共同堅(jiān)守，走到了今天。

圍繞“共創(chuàng)未來(lái)”這一主題，陳民章博士強(qiáng)調(diào)，未來(lái)從來(lái)不是獨(dú)自抵達(dá)的終點(diǎn)，而是在記憶中延續(xù)、在信任中生長(zhǎng)、由選擇攜手同行的人們共同塑造。站在當(dāng)下這個(gè)科學(xué)與技術(shù)持續(xù)突破的時(shí)代，這一共同的未來(lái)正逐漸具象化：全球范圍內(nèi)，已有超過(guò)50萬(wàn)項(xiàng)活躍的臨床試驗(yàn)同步推進(jìn)，每一項(xiàng)都承載著患者的希望。對(duì)藥明康德而言，這個(gè)未來(lái)既承載理想，也扎根現(xiàn)實(shí)。它不僅由思想的交流所點(diǎn)亮，更由責(zé)任的擔(dān)當(dāng)、對(duì)協(xié)作的開(kāi)放、在不確定中前行的勇氣，以及作為一個(gè)共同體持續(xù)向前的承諾所鑄就。而支撐這一切的核心始終清晰而堅(jiān)定：將患者置于每一項(xiàng)決策的中心，持續(xù)踐行那份不曾改變的信念——“讓天下沒(méi)有難做的藥，難治的病”。

健康老齡化的時(shí)代新篇

老齡化不僅是全球社會(huì)面臨的重要趨勢(shì)，更是多種疾病的關(guān)鍵風(fēng)險(xiǎn)因素。“健康老齡化”究竟意味著什么？哪些突破有望改變衰老相關(guān)疾病的進(jìn)程？針對(duì)這些問(wèn)題，來(lái)自學(xué)術(shù)界、生物技術(shù)公司、大型醫(yī)藥企業(yè)與投資機(jī)構(gòu)的專(zhuān)家齊聚一堂，探討延長(zhǎng)“健康壽命”（healthspan）的方法，并展望抗衰老領(lǐng)域正在加速到來(lái)的科學(xué)突破。

Hevolution基金會(huì)首席投資官William Greene博士指出了一個(gè)值得警醒的悖論：過(guò)去半個(gè)世紀(jì)中，人類(lèi)壽命持續(xù)延長(zhǎng)，但新增的壽命年限往往伴隨著日益沉重的慢性疾病負(fù)擔(dān)。他強(qiáng)調(diào)，未能真正“壓低”與年齡相關(guān)疾病的發(fā)生曲線(xiàn)，是現(xiàn)代醫(yī)學(xué)面臨的最大未滿(mǎn)足挑戰(zhàn)之一。同時(shí)，他也將這一現(xiàn)實(shí)視為一次重要機(jī)遇——呼喚全新的醫(yī)學(xué)路徑，不僅要延長(zhǎng)生命長(zhǎng)度，更要提升生命質(zhì)量。

XPRIZE基金會(huì)健康執(zhí)行副總裁Jamie Justice博士從生物學(xué)角度切入，強(qiáng)調(diào)多種老齡相關(guān)疾病背后存在著共通的生物學(xué)基礎(chǔ)。她認(rèn)為，與其將這些疾病視為彼此孤立的狀態(tài)，不如將“衰老本身”視為一個(gè)可干預(yù)的共同靶點(diǎn)。基于動(dòng)物模型和轉(zhuǎn)化研究的證據(jù)，她指出，科學(xué)界正逐步具備調(diào)控這一生物學(xué)過(guò)程的能力，從而有望同時(shí)影響多種疾病。她同時(shí)強(qiáng)調(diào)，XPRIZE正致力于推動(dòng)這些科學(xué)洞見(jiàn)進(jìn)入臨床試驗(yàn)階段，標(biāo)志著老齡化研究正從理論走向現(xiàn)實(shí)驗(yàn)證。

諾和諾德醫(yī)學(xué)與轉(zhuǎn)化科學(xué)高級(jí)副總裁兼首席醫(yī)學(xué)官Filip Knop博士則將新興的長(zhǎng)壽科學(xué)與早已被反復(fù)驗(yàn)證的健康老齡化驅(qū)動(dòng)因素聯(lián)系起來(lái)。他指出，熱量限制和身體活動(dòng)在臨床前研究、流行病學(xué)研究以及人群研究中始終表現(xiàn)出一致的積極作用。他進(jìn)一步介紹，以司美格魯肽為代表的療法，可能正是通過(guò)作用于這些相同的生物通路，減少能量攝入、支持身體功能，從而帶來(lái)廣泛獲益。更為重要的是，他強(qiáng)調(diào)，越來(lái)越多的證據(jù)表明，壽命與健康壽命之間的關(guān)系并非不可改變，這為有意義的醫(yī)學(xué)干預(yù)提供了現(xiàn)實(shí)可能。

巴克老齡化研究所首席執(zhí)行官Eric Verdin博士闡述了健康老齡化領(lǐng)域的核心科學(xué)命題：許多慢性疾病共享由衰老驅(qū)動(dòng)的共同機(jī)制。他以動(dòng)物模型和百歲老人為例指出，這些機(jī)制是可以被調(diào)控的。尤其值得注意的是，百歲老人一生中真正受到與年齡相關(guān)疾病困擾的時(shí)間比例非常低。Verdin博士認(rèn)為，這一鮮明對(duì)比為“壓縮病程”（compressing morbidity）提供了有力證據(jù)——醫(yī)學(xué)目標(biāo)不應(yīng)僅是延長(zhǎng)壽命，更應(yīng)是縮短患病時(shí)間，這在生物學(xué)上是可以實(shí)現(xiàn)的。

Retro Biosciences首席執(zhí)行官Joe Betts-LaCroix先生則聚焦于那些已被證明能夠顯著改善健康壽命的干預(yù)手段。他強(qiáng)調(diào)，熱量限制、GLP-1受體激動(dòng)劑以及身體活動(dòng)，是目前識(shí)別出的最具影響力的幾大杠桿。其中，運(yùn)動(dòng)可能是一種被嚴(yán)重低估的干預(yù)方式。他提到，隨著“運(yùn)動(dòng)因子（exerkines）”研究的興起，科學(xué)家正逐步揭示身體活動(dòng)背后的分子機(jī)制，這也為將相關(guān)生物學(xué)發(fā)現(xiàn)轉(zhuǎn)化為可規(guī)模化的預(yù)防策略打開(kāi)了廣闊空間。

作為本場(chǎng)討論的主持人，Life Biosciences首席運(yùn)營(yíng)官M(fèi)ichael Ringel博士將衰老定義為人類(lèi)所面臨的最普遍、也最具深遠(yuǎn)影響的生物學(xué)狀態(tài)。他指出，衰老遠(yuǎn)比大多數(shù)人想象得更早開(kāi)始，體能和認(rèn)知功能的可測(cè)下降，甚至在生命的第三個(gè)十年便已出現(xiàn)。他進(jìn)一步強(qiáng)調(diào)，在發(fā)達(dá)國(guó)家，超過(guò)90%的發(fā)病率和死亡率都源于與年齡相關(guān)的疾病。因此，健康老齡化并非小眾的科學(xué)議題，而是關(guān)乎醫(yī)療體系、科研優(yōu)先級(jí)乃至整個(gè)社會(huì)的核心挑戰(zhàn)。

阿爾茨海默病：從全球挑戰(zhàn)看未來(lái)健康

作為老年人群中最常見(jiàn)的神經(jīng)退行性疾病之一，阿爾茨海默病既是“健康老齡化”進(jìn)程中的嚴(yán)峻挑戰(zhàn)，也是一場(chǎng)對(duì)生物醫(yī)藥行業(yè)創(chuàng)新能力與應(yīng)對(duì)策略的系統(tǒng)性考驗(yàn)。達(dá)沃斯阿爾茨海默病協(xié)作組織創(chuàng)始主席George Vradenburg先生與F-Prime生物醫(yī)學(xué)研究倡議總裁Stacie Weninger博士，把阿爾茨海默病視作對(duì)全球醫(yī)療體系的一次“壓力測(cè)試”。在這場(chǎng)對(duì)話(huà)中，他們深入探討科學(xué)創(chuàng)新如何實(shí)現(xiàn)有效轉(zhuǎn)化，以及如何提升療法的可及性、可負(fù)擔(dān)性與全球落地能力。

Stacie Weninger博士強(qiáng)調(diào)，需要重新思考神經(jīng)退行性疾病的研究與治療路徑，尤其是在有效療法仍然有限的領(lǐng)域。她指出，研究本身應(yīng)當(dāng)越來(lái)越多地發(fā)揮“護(hù)理”的功能，像腫瘤領(lǐng)域那樣，讓患者更早獲得研究性療法，從而在滿(mǎn)足迫切未滿(mǎn)足需求的同時(shí)，加速研發(fā)進(jìn)程。她特別強(qiáng)調(diào)，生物標(biāo)志物的快速演進(jìn)是這一轉(zhuǎn)變的核心驅(qū)動(dòng)力——從最初依賴(lài)尸檢診斷，到影像學(xué)，再到如今的腦脊液和血液標(biāo)志物，這一系列進(jìn)展正在根本性地重塑阿爾茨海默病的發(fā)現(xiàn)、研究與治療方式。

George Vradenburg先生則強(qiáng)調(diào)了可規(guī)模化、低成本技術(shù)在改變阿爾茨海默病全球軌跡方面的巨大潛力。他提到，基于語(yǔ)音的認(rèn)知評(píng)估等新工具，有望突破傳統(tǒng)臨床場(chǎng)景的限制，實(shí)現(xiàn)更早期、更廣泛的認(rèn)知障礙識(shí)別。通過(guò)智能手機(jī)、數(shù)字平臺(tái)和遠(yuǎn)程醫(yī)療，這些技術(shù)能夠?qū)⒃u(píng)估、監(jiān)測(cè)與干預(yù)真正帶到患者身邊，從而在全球范圍內(nèi)顯著提升腦健康創(chuàng)新的可及性。

專(zhuān)題討論主持、藥明康德聯(lián)席首席執(zhí)行官楊青博士總結(jié)指出，任何挑戰(zhàn)都可能轉(zhuǎn)化為機(jī)遇，而這些機(jī)遇往往會(huì)激發(fā)科學(xué)家提出新的解決方案。同時(shí)，盡管任何新技術(shù)和新分子在起步階段往往成本不菲，但隨著行業(yè)了解的不斷加深，我們終將變得更快，更高效，最終造福更廣泛的患者群體。

塑造未來(lái)研發(fā)新格局

在2026藥明康德全球論壇的最后一場(chǎng)專(zhuān)題討論中，多家知名風(fēng)險(xiǎn)投資機(jī)構(gòu)的代表從投融資視角切入，探討未來(lái)投資方向、技術(shù)平臺(tái)與研發(fā)體系應(yīng)如何演進(jìn)，才能更好承接新技術(shù)浪潮與患者需求。同時(shí)，他們也分享了如何通過(guò)更高效的協(xié)作模式，推動(dòng)行業(yè)取得更快的進(jìn)展與更優(yōu)的創(chuàng)新成果。

賽諾菲投資董事總經(jīng)理Jason Hafler先生從務(wù)實(shí)、以生態(tài)體系為先的視角出發(fā)，強(qiáng)調(diào)大型制藥企業(yè)在推動(dòng)創(chuàng)新方面所具備的多元化、靈活工具組合。他指出，創(chuàng)新者與制藥伙伴之間保持清晰、透明的溝通至關(guān)重要。無(wú)論是并購(gòu)、業(yè)務(wù)拓展還是股權(quán)投資，圍繞需求達(dá)成共識(shí)，都是高效穿越復(fù)雜組織結(jié)構(gòu)、加速將藥物帶給患者的關(guān)鍵。

Flagship Pioneering普通合伙人Avak Kahvejian博士則將行業(yè)置于他所稱(chēng)的“生物學(xué)世紀(jì)”之中，對(duì)AI推動(dòng)藥物研發(fā)成功率提升持長(zhǎng)期樂(lè)觀態(tài)度。他以25年的時(shí)間尺度指出，一場(chǎng)低調(diào)卻深刻的變革已然展開(kāi)——更理性、更有針對(duì)性的研發(fā)方式，正逐步降低失敗率、壓縮成本，并擴(kuò)大健康壽命改善的全球可及性。

Aulis Capital經(jīng)營(yíng)合伙人Nisa Leung女士聚焦當(dāng)下的融資環(huán)境，指出資本紀(jì)律已成為成功創(chuàng)新的決定性特征。她認(rèn)為，真正具備長(zhǎng)期影響力與回報(bào)潛力的公司，往往由精干、高效、強(qiáng)調(diào)執(zhí)行力與創(chuàng)新精神的創(chuàng)業(yè)者所領(lǐng)導(dǎo)。在資金趨緊的環(huán)境中，每一美元都必須發(fā)揮更大的價(jià)值，這不僅塑造著企業(yè)行為，也在重塑研發(fā)本身的形態(tài)。

VZVC聯(lián)合創(chuàng)始人兼經(jīng)營(yíng)合伙人Vijay Pande博士展望了一個(gè)公共健康預(yù)期發(fā)生根本轉(zhuǎn)變的未來(lái)——醫(yī)學(xué)將從“治療疾病”逐步轉(zhuǎn)向“預(yù)防疾病”。他認(rèn)為，預(yù)防與長(zhǎng)壽將成為醫(yī)療體系的重要支柱，而AI在很大程度上將改變醫(yī)療服務(wù)的經(jīng)濟(jì)學(xué)基礎(chǔ)。盡管這一愿景頗具挑戰(zhàn)性，但他強(qiáng)調(diào)，其底層基礎(chǔ)已在逐步建立。

Sofinnova Partners經(jīng)營(yíng)合伙人Henrijette Richter博士強(qiáng)調(diào)了歐洲作為全球生物技術(shù)創(chuàng)新引擎的崛起。她指出，歐洲長(zhǎng)期積累的科研實(shí)力，正越來(lái)越多地與充沛的私人資本相結(jié)合。更大規(guī)模的基金、更深層次的協(xié)作以及來(lái)自美國(guó)投資者的持續(xù)關(guān)注，正共同構(gòu)成一個(gè)正向循環(huán)，推動(dòng)歐洲在全球研發(fā)版圖中扮演更加重要、開(kāi)放且具有競(jìng)爭(zhēng)力的角色。

Canaan Partners普通合伙人Tim Shannon博士則將討論重新拉回到分子層面，重點(diǎn)介紹了“誘導(dǎo)鄰近效應(yīng)（induced proximity）”這一創(chuàng)新作用機(jī)制。他指出，該策略能夠解鎖傳統(tǒng)治療模式難以觸及的全新生物學(xué)問(wèn)題，并以可規(guī)模化的小分子方案實(shí)現(xiàn)突破。在兼顧創(chuàng)新性、可制造性與成本效率的前提下，這類(lèi)技術(shù)有望將先進(jìn)療法惠及更廣泛的患者群體。

楊青博士也用三個(gè)關(guān)鍵詞為本場(chǎng)討論，以及本次藥明康德全球論壇做了總結(jié)：第一個(gè)關(guān)鍵詞是“樂(lè)觀”——在放晴的舊金山，現(xiàn)場(chǎng)切實(shí)感受到一種強(qiáng)烈的樂(lè)觀情緒；第二個(gè)關(guān)鍵詞是“勇敢新世界”——革命性的技術(shù)正深刻改變著整個(gè)產(chǎn)業(yè)和生態(tài)圈；第三個(gè)關(guān)鍵詞是“振奮”——論壇嘉賓們的分享，也描繪出了通往2026年及未來(lái)的巨大機(jī)遇。

同行致遠(yuǎn)

整場(chǎng)論壇以特邀嘉賓、著名詩(shī)人及劇作家Jon Goode先生的思考和靈感作為精神主線(xiàn)，其文字貫穿論壇的開(kāi)幕、中場(chǎng)與閉幕。通過(guò)三個(gè)精心編排的篇章，他道出了全球生命科學(xué)界共同的目標(biāo)：真正的創(chuàng)新，不只是技術(shù)的飛躍或時(shí)間表上的節(jié)點(diǎn)，更關(guān)乎每一個(gè)決策背后所影響的真實(shí)人生。他的文字抓住了合作、責(zé)任，以及眾人攜手前行的力量的本質(zhì)，也讓在場(chǎng)的每一位有機(jī)會(huì)停下腳步，重新思考初心，并再次承諾：我們要做的，是把生的希望，真正變成可及的“治愈性”突破。

當(dāng)論壇接近尾聲，他的詩(shī)句依然在人們心中回響——它們印證了這一天反復(fù)傳遞的信念：醫(yī)學(xué)的進(jìn)步，從來(lái)不是一個(gè)人的孤勇，而是無(wú)數(shù)人懷著共同使命，并肩前行，為全球患者、家庭和社區(qū)一起創(chuàng)造的未來(lái)。

WuXi Global Forum 2026: Together, We Advance Breakthroughs for Patients

At the dawn of the new millennium in 2000, humanity caught its first glimpse of life’s blueprint. In that defining moment, a dream for medicine was kindled—to understand disease more deeply, to design therapies with greater wisdom, and to bring transformative treatments within reach of countless lives. It was also in that very year that WuXi AppTec was born—founded on a shared vision with innovators around the world, turning that dream into a steadfast commitment.

For 25 years, this dream has never remained merely an idea. It has taken root in laboratories, flourished in clinics, and grown steadily through collaboration, trust, and unwavering dedication.

Now, standing at the threshold of 2026, the 14th WuXi AppTec Global Forum gathers once again in San Francisco. Dreamers and doers from across the globe reunite under the banner of “B.O.L.D.”—to reflect on a journey of 25 remarkable years, and to gaze toward the dreams still unfolding ahead.

To all who have believed in science, championed innovation, and moved medicine forward through action—this is our tribute to you.

WELCOME

Opening the 14th WuXi Global Forum, Dr. Hui Cai, Program Chair and Vice President of WuXi AppTec, reflected on a journey that began 25 years ago, when science was filled with BOLD ideas and the belief that progress is made by moving forward together. From the optimism of the year 2000 to today’s accelerating pace of discovery, she noted that the advances shaping modern medicine have always been driven by collective courage, shared purpose, and a willingness to act on possibility.

Revisiting the Forum’s enduring theme of "BOLD":Breaking barriers, Opening new horizons, Leading the next-generation healthcare solutions, and Delivering on promises for patients,Dr. Cai emphasized that boldness today also means clarity and focus amid a noisy world.The future WuXi AppTec envisions, she underscored, is not built by one company alone, but by a global community advancing together.

STATE OF INNOVATION

Standing at the beginning of the next 25 years of this century, we are prompted to reflect on the journey so far:what remarkable breakthroughs has the industry achieved, and what bottlenecks still remain to be addressed?In the opening session, “State of Innovation,” a distinguished group of speakers revisited the past, assessed the present, and jointly explored future directions from multiple perspectives, including translational innovation, clinical development, regulation, and investment.

Dr. Juergen Eckhardt, EVP, Head of Pharmaceuticals BD&L and Head of Leaps by Bayer, reflected on the emergence of new modalities in the past quarter of century. He said: "I think it was a stunning period, probably unprecedented in terms of new modalities being developed and, most importantly, being made available to patients.It has really changed patient treatment paradigms for many patients in need."

While acknowledging the progress, Dr. Kenneth Kaitin, Professor and Senior Fellow at Tufts Center for the Study of Drug Development, also noted that"the process of drug development has remained basically the same for over 60 years, and that's created some interesting challenges for the industry."

Among the challenges faced by the industry, improving clinical trial efficiency is on top of many panelists' minds. Dr. Giulio Draetta, SVP and Chief Scientific Officer of MD Anderson Cancer Center, pointed out that contrary to the notion that patients would not want to go through complex clinical trials, there is a lot of generosity coming from the patients and wanting to provide an opportunity for early investigations.Better execution in unifying standard care and clinical trials may dramatically increase the participation of clinical trials.

Dr. Mathai Mammen, Chairman, President & CEO of Parabilis Medicines, offered his perspective on clinical trials for rare disease patients. He said: "My advocacy for all patients that suffer from rare diseases would be thatcompanies need to work very hard to use general screening information to find patients that have the condition that's wrong.So that will help substantially in clinical trial conduct for anyone working within anything but well-known diseases."

One of the technologies that can be used to improve clinical trials is artificial intelligence (AI). Dr. David Berry, Co-Founder and Managing Partner of Averin Capital offered a tantalizing prospect on the impact of AI on clinical trials.He said with AI, it is possible to do simulations of clinical studies, to the point that the FDA allowed researchers to do a study where they never contacted a patient with drug.Even though replacing clinical trial with AI simulation was considered impossible by many.

Speaking of tackling "the impossible", session moderator, Dr. Laura Shawver, Venture Partner at RA Ventures brought up one of her favorite quote, "the difficult we do immediately, the impossible takes a little longer." She believes in the coming years, we will tackle the impossible, whether we believe it's possible today or possible in the future.

BREAKING THROUGH IN THE FAST LANE

Transforming scientific discovery into therapies that truly benefit patients remains one of the industry’s core challenges.How should we make decisions in advancing innovative medicines? And how can innovation be better aligned with the most pressing unmet medical needs? In the panel discussion “Breaking Through in the Fast Lane,” leaders from several cutting-edge companies shared practical measures and strategies to accelerate drug R&D, challenged traditional development models, and explored new technologies, approaches, and concepts designed to improve both efficiency and success rates.

Session moderator, Dr. Jon Edwards, Partner at Forbion, kicked off the discussion by asking "What does speed mean?Is speed raising the most money and having a really large war chest and being able to just move quickly? Is it an experienced team that's not going to make mistakes? Is it AI, which is going to solve all of our problems?"

On the prospect of AI in accelerating drug discovery, Dr. Paulo Fontoura, Chief Medical Officer of Xaira Therapeutics said he is an AI optimist. He said: "Obviously AI can accelerate a lot of these things. But it's not just acceleration. It's acceleration to truth finding, and that's really the key thing here.I really think that what AI can do is not only allow us to understand better the biology, but also fit those biologies to the right patients, and therefore deliver more results for them."

In addition to AI, Dr. Tony Estrada, President & CEO of Tenvie Therapeutics, emphasized the importance of careful design in clinical trials. He said in the CNS disease space,sometimes moving too fast actually was doing the target and the biology a disservicebecause then we make incorrect hypotheses or conclusions thatset the field back.

Panelists also addressed the mindset of how to make better medicines faster. Dr. Sabah ?ney, CEO of Dispatch Bio, stressed the urgency demanded by the patients. He said: "We're in solid tumors. Those patients that we are trying to treat are, at the end of life, they have seven or eight months left. They're someone's father, someone's wife, or other sister.And if we are even two years late, that's thousands of patients that we could have impacted but that we didn't impact."

Dr. Ken Song, Chairman, President & CEO of Candid Therapeutics, talked about the mindset to design "the right experiment so I can kill the program and shut the company down as fast as I can? If you can't do that, then you have the drug. Butif you do the right experiment,you shut the company down fast, then I think that's better. And that makes us more efficient."

DELIVERING ON THE PROMISE OF CELL AND GENE THERAPIES

As one of the fastest-growing therapeutic modalities in recent years, cell and gene therapies have brought new hope to patients with a wide range of cancers and genetic diseases.In the fireside chat “Delivering on the Promise of Cell and Gene Therapies,” 2025 Nobel Prize in Physiology or Medicine laureate Dr. Fred Ramsdell joined Dr. Jeffrey Bluestone, Founder and Advisor of Sonoma Biotherapeutics to review the historical evolution and current landscape of the field. Together, they discussed how Nobel-winning research on regulatory T-cells has laid the scientific foundation for using cell therapy to treat autoimmune diseases, and looked ahead to future expansion opportunities in cell and gene therapy.

Dr. Jeffrey Bluestone noted that Dr. Fred Ramsdell's Nobel winning research revealed thatimmune tolerance is not the absence of immunity, it's really an active process built on the evolutionary pressures to preserve one's own tissue and allow the immune system to still simultaneously recognize and destroy foreign agents.So regulatory T cells (Tregs) are not accidents of biology, they're actually a lineage that evolved to actually perform these activities and every autoimmune disease that we struggle with, every transplant that's rejected is directly connected to an inability of these cells to do their job the way we want them to do it. So we can now imagine a whole array of drugs that can be developed.

Dr. Fred Ramsdell highlighted the difference between Tregs therapy compared to other drug modalities. He said: "What I love about this modality is that we're taking advantage of what evolution has devised to control our immune responses. These cells are really smart, because they had thousands and tens and hundreds of thousands of years to develop to do things.They know where to go and what to do. I can let the cell that's evolved to take care of the tissue, take care of the tissue."

WHAT SHOULD WE STRIVE TOWARD FOR PATIENTS

Ultimately, scientific breakthroughs and technological advances must translate into meaningful improvements in people’s lives.In the panel “What Should We Strive Toward for Patients” moderated by Dr. Harvey Berger, Chairman & CEO of Arena BioWorks, three scientists with extensive frontline clinical experience — including 2025 Breakthrough Prize laureate Dr. Stephen Hauser, Parker Institute for Cancer Immunotherapy CEO Dr. Karen Knudsen, and Director of Stanford Cardiovascular Institute Dr. Joseph Wu — discussed developments in oncology, cardiovascular disease and neuroscience. They explored which treatment and prevention strategies can truly reshape patient outcomes, and how more patient-centered R&D approaches can drive meaningful, real-world innovation.

Session moderator Dr. Harvey Berger opened the discussion by noting that in his opinion,the fundamental problem facing drug discovery and development is the rather high failure rate."The failure rate is way too high. If that was 50%, speed wouldn't be the issue. We would have a dramatic and profound difference, I think, for patients."

Dr. Joseph Wu was optimistic thatwith advance in technology,the failure rate will hopefully come down in the future.He said: "30-40 years ago, we don't really have access to tissues. Even if we do, all we do is do an H&E staining. Right now you can take the human tissues, do single cell proteomics, single cell sequencing, single nuclear sequencing, figure out exactly what gene goes up, goes down, what proteins are altered. Take those genes and take those proteins, go back to the lab and figure out what type of a drug can modulate that gene, modulate that protein and then go back to the lab again to use all these organoids that we have at our disposal to figure out which one of these really work and then go back to the patient."

Dr. Karen Knudsen highlighted the achievements in novel cancer treatments. She said: "We are at the first time in this country that we have a 70% five-year survival rate for all 200 cancers in aggregate.That is an incredible moment. And when you unpack what happens there, it came from innovations in therapeutics in difficult to treat cancers."

Dr. Stephen Hauser is hopeful that with the advance in biomarkers, the future for treating neurodegenerative diseases is bright. He said: "These diseases are biologically so much simpler than they were 10 years ago. Alzheimer, Parkinson, ALS, Huntington.We can understand the pathways, understand what can be drug targeted, and I think projects that are very robust, that go after reasonable targets, are going to have a chance to dramatically improve the lives of billions of people."

THE FUTURE WE SHARE

In his remarks, Dr. Minzhang Chen, Co-CEO of WuXi AppTec, expressed his sincere appreciation to the speakers, customers, partners, investors, and friends who have contributed their insights, trust, and commitment. He reflected on the shared journey that began in 2000, when WuXi AppTec was founded with just four people and a 7,000 square foot chemistry lab, guided by a simple belief that science could change lives. Over the past 25 years, he noted, WuXi AppTec’s growth has been inseparable from the global innovation community that supported it: pushing the boundaries of science, taking risks, and remaining committed through both favorable and challenging times.

Reflecting on the session theme, “The Future We Share,” Dr. Chen underscored that the future is never built in isolation; it is shaped by memory, by trust, and by the people who choose to walk the road together. In today’s era of accelerating scientific and technological breakthroughs, he noted, that shared future is taking shape through more than half a million active clinical trials worldwide, each representing a beacon of hope for patients. For WuXi AppTec, this future is both aspirational and deeply practical, powered by over 10,000 medicines currently in the global pipeline, and many more yet to come. It is a future defined not merely by ideas exchanged, but by responsibility embraced, by openness to collaboration, by the courage to advance amid uncertainty, and by a collective commitment to move forward as one community.At the heart of this shared horizon lies a simple yet unwavering principle: to place patients at the center of every decision, and to continue pursuing WuXi AppTec’s enduring vision that “every drug can be made, and every disease can be treated”.

SPOTLIGHT ON HEALTHY AGING

Population aging is not only a defining global demographic trend, but also a major risk factor for numerous diseases, with profound implications for both life expectancy and quality of life. What does “healthy aging” truly mean? And which breakthroughs have the potential to alter the course of aging-related disease? In the session “Spotlight on Healthy Aging,” experts from academia, biotechnology companies, leading pharmaceutical organizations, and investment institutions came together to discuss strategies for extending healthspan, while exploring the wave of scientific progress now emerging in the field of aging research.

Dr. William Greene, Chief Investment Officer at Hevolution Foundation, highlighted a sobering paradox: while lifespan has steadily increased over the past half-century, those added years have largely been accompanied by a growing burden of chronic disease. He noted that the failure to meaningfully bend the curve of age-related illness represents one of the greatest unmet challenges in modern medicine. At the same time,he framed this reality as a powerful opportunity; one that calls for new approaches capable of extending not just how long people live, but how well they live.

Dr. Jamie Justice, EVP of Health at XPRIZE Foundation, emphasized the unifying biology underlying many age-related diseases, arguing thataging itself offers a shared target for intervention rather than a collection of isolated conditions. Drawing on evidence from animal models and translational research, she highlighted the growing ability to modulate this biology in ways that could impact multiple diseases simultaneously. She underscored XPRIZE’s focus on advancing these insights into clinical trials, signaling a shift from theoretical promise to real-world validation.

Dr. Filip Knop, Chief Medical Officer, SVP Medical & Translational Science at Novo Nordisk, connected emerging longevity science with well-established drivers of healthy aging, pointing to caloric restriction and physical activity as consistent factors across preclinical, epidemiological, and human studies.He described how therapies such as semaglutide may deliver broad benefits by acting on these same biological pathways, reducing caloric intake and supporting physical function.Importantly, he emphasized that growing evidence suggests the relationship between lifespan and healthspan is not fixed, reinforcing the possibility of meaningful intervention.

Dr. Eric Verdin, CEO of The Buck Institute for Research on Aging, articulated the central scientific promise of the healthy aging field: that many chronic diseases share common aging-driven mechanisms.He highlighted both animal models and human centenarians as compelling evidence that these mechanisms can be modulated, noting that centenarians spend a remarkably small fraction of their lives affected by age-related disease.This contrast, he argued, offers a powerful proof point that compressing morbidity – and not just extending life – is biologically achievable.

Joe Betts-LaCroix, CEO of Retro Biosciences, focused on the emerging biological understanding of interventions that meaningfully improve healthspan, emphasizing caloric restriction, GLP-1 agonists, and physical activity as some of the most impactful levers identified to date. He highlighted exercise as a particularly underutilized intervention, pointing to the growing field of “exerkines” as researchers begin to unravel the molecular mechanisms underlying physical activity.His remarks underscored the breadth of untapped opportunity in translating these biological insights into scalable, preventative strategies.

Serving as the session leader,Dr. Michael Ringel,COO of Life Biosciencesframed aging as the most universal, and consequential, biological condition facing humanity.He emphasized that aging begins far earlier than most people realize, with measurable declines in physical and cognitive function starting as early as the third decade of life. By underscoring that more than 90% of morbidity and mortality in the developed world stems from age-related diseases, he positioned healthy aging not as a niche scientific pursuit, but as a central challenge for healthcare systems, research priorities, and society at large.

ALZHEIMER'S: WHAT A GLOBAL CHALLENGE REVEALS ABOUT THE FUTURE OF HEALTH

As one of the most common neurodegenerative diseases among older adults, Alzheimer’s disease represents both a serious challenge within the broader healthy-aging agenda and a critical test of the biopharmaceutical industry’s capacity for innovation and response. Under moderation of Dr. Steve Yang, Co-CEO of WuXi AppTec, George Vradenburg, Founding Chairman of the Davos Alzheimer’s Collaborative, and Dr. Stacie Weninger, President of the F-Prime Biomedical Research Initiative, framed Alzheimer’s disease as a “stress test” for global healthcare systems. Their discussion examined how scientific innovation can be effectively translated into practice and how accessibility, affordability, and global adoption of therapies can be improved.

Dr. Stacie Weninger emphasized the need to rethink how neurodegenerative diseases are approached, particularly in areas where effective treatments remain limited. She argued that research itself must increasingly function as a form of care, expanding patient access to investigational therapies earlier, much as oncology has done, in order to accelerate development while addressing urgent unmet needs.Central to this shift, she underscored, is the rapid evolution of biomarkers,noting the field’s progression from post-mortem diagnosis to advanced imaging and, more recently, to CSF and blood-based biomarkers that are fundamentally reshaping how diseases like Alzheimer’s can be detected, studied, and ultimately treated.

George Vradenburg highlighted the transformative potential of scalable, low-cost technologies to change the global trajectory of Alzheimer’s disease. He pointed to emerging tools such as blood-spot testing and voice-based detection systems as breakthroughs that could enable early identification of cognitive impairment far beyond traditional clinical settings.By leveraging smartphones, digital platforms, and telehealth, he described a future in which assessment and treatment can reach patients worldwide,bringing detection, monitoring, and care closer to where people live, and fundamentally expanding access to brain health innovation.

Dr. Steve Yang, Co-CEO of WuXi AppTec and session leader, pointed out thatevery challenge has the potential to become an opportunity — an opportunity for scientists to innovate and develop new solutions. Also, the unit cost of new technologies and new modalites could be very high at the beginning. Butas the industry moves along the learning curve, we learn to do things faster and more cost-effectively while maintaining the same quality and efficiency. Over time, those costs come down, which in turn drives broader adoption.

DEFINING THE NEXT ERA OF R&D

In the panel discussion “Defining the Next Era of R&D,” representatives from leading venture capital firms discussed how technology platforms and R&D systems must evolve to meet emerging scientific opportunities and patient needs, and how more effective models of collaboration can help the industry achieve faster progress and deliver better innovative solutions.

Dr. Jason Hafler, Managing Director of Sanofi Ventures, framed the future of R&D through a pragmatic, ecosystem-first lens,emphasizing that large pharmaceutical organizations bring a diverse and flexible set of tools to advance innovation.He highlighted the importance of clarity and transparency between innovators and pharma partners, underscoring that alignment on needs, whether through M&A, business development, or equity investment, is critical to efficiently navigating complex organizations and ultimately getting medicines to patients faster.

Dr. Avak Kahvejian, General Partner at Flagship Pioneering,situated the industry firmly within what he described as the “biological century,” expressing long-term optimism that advances in AI will dramatically improve the probability of success in drug discovery.Looking out over a 25-year horizon, he pointed to a quiet but meaningful transformation already underway – one in which smarter, more deliberate approaches to R&D are beginning to reduce attrition, lower costs, and enable broader global access to improved healthspan.

Dr. Nisa Leung, Managing Partner of Aulis Capital, focused on the realities of today’s funding environment, noting that capital discipline has become a defining feature of successful innovation.She emphasized that the companies poised to deliver both outsized impact and returns are those led by frugal, fast-moving entrepreneurs who prioritize efficiency and innovation.In a constrained funding climate, she underscored that every dollar must work harder, shaping not only company behavior, but the future contours of R&D itself.

Dr. Vijay Pande, Co-Founder and Managing Partner at VZVC, looked ahead to a future in which public expectations of medicine fundamentally shift – from treating disease to preventing it altogether.He described prevention and longevity as emerging pillars of healthcare, enabled in large part by AI’s ability to transform the economics of care delivery.While ambitious, he argued that the foundations for this future are already being laid, signaling a broader redefinition of what success in medicine will mean over the next 25 years.

Dr. Henrijette Richter, Managing Partner at Sofinnova Partners,highlighted Europe’s growing strength as a global engine of biotech innovation,pointing to its long-standing scientific excellence now increasingly matched by robust private capital. She described a positive, reinforcing cycle – larger European funds, deeper collaboration, and rising interest from U.S. investors – as evidence that Europe’s role in shaping the future of R&D is expanding, collaborative, and globally competitive.

Dr. Tim Shannon, General Partner at Canaan Partners, brought the discussion back to the molecular level,spotlighting induced proximity as a powerful example of how next-generation pharmacology can unlock entirely new therapeutic possibilities.He emphasized that this approach enables scalable, small-molecule solutions capable of addressing biological problems beyond the reach of traditional modalities. By combining novelty with manufacturability and cost efficiency, he underscored how such innovations can extend the reach of advanced therapies to large patient populations worldwide.

Dr. Steve Yang summarized this panel, as well as the WuXi Global Forum, in three key words. First isoptimism: there is a palpable sense of optimism throughout the discussions today. Second is “brave new world”, as transforming technology will fundamentally reshape the entire industry ecosystem. And finally, here and now, it’s clear that there are tremendous opportunities — and realexcitement— as we look ahead to 2026.

REINFORCING THE SHARED SPIRIT OF INDUSTRY

Tying the forum together was a powerful throughline of reflection and inspiration from special guest Jon Goode, whose spoken-word performance wove together the opening, midpoint, and closing moments of the day. Through three thoughtfully crafted segments, he gave voice to the shared purpose that underpins the global life sciences community, reminding the audience that innovation is not only about technologies or timelines, but about the human lives touched by every decision made along the way. His words captured the essence of collaboration, responsibility, and shared strength, offering a moment to pause, reflect, and recommit to advancing breakthroughs that turn hope into healing. As the final notes of the forum settled, his message echoed what the day had made clear: progress in medicine is built together, sustained by purpose, and driven forward for patients, families, and communities around the world.

免責(zé)聲明：本文僅作信息交流之目的，文中觀點(diǎn)不代表藥明康德立場(chǎng)，亦不代表藥明康德支持或反對(duì)文中觀點(diǎn)。本文也不是治療方案推薦。如需獲得治療方案指導(dǎo)，請(qǐng)前往正規(guī)醫(yī)院就診。

版權(quán)說(shuō)明：歡迎個(gè)人轉(zhuǎn)發(fā)至朋友圈，謝絕媒體或機(jī)構(gòu)未經(jīng)授權(quán)以任何形式轉(zhuǎn)載至其他平臺(tái)。轉(zhuǎn)載授權(quán)請(qǐng)?jiān)凇杆幟骺档隆刮⑿殴娞?hào)回復(fù)“轉(zhuǎn)載”，獲取轉(zhuǎn)載須知。